© 1994 by Oxford University Press
Journal of the National Cancer Institute, Vol. 86, No. 9, 681-687,
May 4, 1994
© 1994 Oxford University Press
Cytoplasmic Accumulation of p53 Protein: an Independent Prognostic Indicator in Colorectal Adenocarcinomas
Department of Pathology, University of Milan School of Medicine Italy
Department of Colorectal Surgery, Lahey Clinic Medical Center Burlington, Mass
Department of Anatomic Pathology, Lahey Clinic Medical Center; Department of Pathology, New England Deaconess Hospital and Harvard Medical School Boston, Mass
Correspondence to: Silvano Bosari, M.D., Department of Pathology, Ospedale San Paolo, Via di Rudini 8, 20142 Milan, Italy.
BACKGROUND:: Aberrations of the p53 gene (also known as TP53) frequently lead to the synthesis of mutant proteins that accumulate in the nuclei and/or cytoplasm of neoplastic cells. Intracellular p53 protein accumulation may be an unfavorable prognostic parameter in breast, lung, ovarian, gastric, and colorectal cancers. Specific classes of p53 gene mutations, assayed by characteristic subcellular p53 protein accumulation patterns, may be useful prognostic indicators. Purpose: The prognostic value of nuclear and cytoplasmic p53 protein accumulation in the tumor cells of patients with colorectal carcinoma was studied. Methods: Antibodies PAb 1801 and CM1 were used for immunocyto-chemical assay of nuclear and cytoplasmic p53 protein accumulation in a retrospective series of colorectal carcinoma samples obtained from 206 patients who were followed for at least 5 years. Results were correlated with the following clinicopathologic parameters: patient sex and age; tumor site, stage, and grade; and DNA ploidy status of the tumors. Overall survival and disease-free survival were analyzed with the Kaplan-Meier method. Differences in distributions were analyzed using the Mantel—Cox method. Multivariate analysis was performed with the Cox proportional hazards model. Results: Immunostaining with PAb 1801 revealed nuclear p53 accumulation in 46% (95) of 206 cases, whereas CM1 immunostaining of 197 cases showed nuclear and cytoplasmic p53 accumulation in 33% (65 cases) and 50% (99 cases) of the cases, respectively. In univariate analysis, both nuclear p53PAb 1801 and cytoplasmic p53CM1 protein accumulations were significantly associated with poor overall survival (P =.0198 and P =.0017, respectively) and with disease-free survival (P =.004 and P =.0016, respectively). When patients were analyzed according to site of their tumors, nuclear p53PAb 1801 protein accumulation was statistically significant only in the right colon (P =.027), whereas cytoplasmic p53CM1 protein accumulation was statistically significant in the left colon and rectum (P =.0016). In multivariate analysis, only cytoplasmic p53CM1 protein accumulation was associated with poor overall survival and with disease-free survival (P =.006 and P =.002, respectively). With the addition of DNA ploidy status, however, cytoplasmic p53CM1 protein accumulation remained significant only for disease-free survival (P =.035). In patients with tumors of the left colon and rectum, cytoplasmic p53CM1 protein accumulation was the most significant prognostic indicator for overall survival (P =.007) and disease-
free survival (P =.002) after disease stage. Conclusion: Cytoplasmic p53CM1 protein accumulation, but not nuclear p53PAb 1801 protein accumulation, is an independent prognostic parameter in patients with colorectal carcinomas. Implications: Cytoplasmic p53CM1 accumulation may be a useful indicator of patients at high risk for disease recurrence who may benefit from aggressive adjuvant therapy. [J Natl Cancer Inst 86: 681–687, 1994]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Das, K. Wojno, and M. J. Imperiale BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages J. Virol., March 15, 2008; 82(6): 2705 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al. Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study J. Clin. Oncol., May 1, 2004; 22(9): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tang, C. R. Changchien, M.-C. Wu, C.-W. Fan, K.-W. Liu, J.-S. Chen, H.-T. Chien, and L.-L. Hsieh Colorectal cancer without high microsatellite instability and chromosomal instability--an alternative genetic pathway to human colorectal cancer Carcinogenesis, May 1, 2004; 25(5): 841 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Qu, S. Huang, D. Baltzis, A.-M. Rivas-Estilla, O. Pluquet, M. Hatzoglou, C. Koumenis, Y. Taya, A. Yoshimura, and A. E. Koromilas Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3{beta} Genes & Dev., February 1, 2004; 18(3): 261 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Ropponen, J K Kellokoski, R T Pirinen, K I Moisio, M J Eskelinen, E M Alhava, and V-M Kosma Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation J. Clin. Pathol., July 1, 2001; 54(7): 533 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ottaggio, S. Bozzo, F. Moro, A. Sparks, P. Campomenosi, M. Miele, S. Bonatti, G. Fronza, D. P. Lane, and A. Abbondandolo Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification Carcinogenesis, September 1, 2000; 21(9): 1631 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang Evaluation of Four Antibodies in Detecting p53 Protein for Predicting Clinicopathological and Prognostic Significance in Colorectal Adenocarcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4126 - 4132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mamounas, S. Wieand, N. Wolmark, H. D. Bear, J. N. Atkins, K. Song, J. Jones, and H. Rockette Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04) J. Clin. Oncol., May 1, 1999; 17(5): 1349 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tortola, E. Marcuello, I. Gonzalez, G. Reyes, R. Arribas, G. Aiza, F. J. Sancho, M. A. Peinado, and G. Capella p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1375 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kressner, M. Inganas, S. Byding, I. Blikstad, L. Pahlman, B. Glimelius, and G. Lindmark Prognostic Value of p53 Genetic Changes in Colorectal Cancer J. Clin. Oncol., February 1, 1999; 17(2): 593 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.M. Moll and L.M. Schramm p53--An Acrobat in Tumorigenesis Critical Reviews in Oral Biology & Medicine, January 1, 1998; 9(1): 23 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Ostermeyer, E. Runko, B. Winkfield, B. Ahn, and U. M. Moll Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide PNAS, December 24, 1996; 93(26): 15190 - 15194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Cheng, L.-F. Sheu, C.-L. Meng, and J.-C. Lin Expression of p53 Protein in Colorectal Carcinoids Arch Surg, January 1, 1996; 131(1): 67 - 70. [Abstract] [PDF]
|
|
|
|
 |
|
 K Galaktionov, A. Lee, J Eckstein, G Draetta, J Meckler, M Loda, and D Beach CDC25 phosphatases as potential human oncogenes Science, September 15, 1995; 269(5230): 1575 - 1577. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Takanishi Jr, I. Angriman, M. L. Yaremko, A. Montag, C. A. Westbrook, and F. Michelassi Chromosome 17p Allelic Loss in Colorectal Carcinoma: Clinical Significance Arch Surg, June 1, 1995; 130(6): 585 - 589. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tempero and J. Anderson Progress in Colon Cancer -- Do Molecular Markers Matter? N. Engl. J. Med., July 28, 1994; 331(4): 267 - 268. [Full Text]
|
|